159 related articles for article (PubMed ID: 33226554)
41. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
Tian X; Xu J; Dorfman DM
Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
[TBL] [Abstract][Full Text] [Related]
42. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Ennishi D; Takata K; Béguelin W; Duns G; Mottok A; Farinha P; Bashashati A; Saberi S; Boyle M; Meissner B; Ben-Neriah S; Woolcock BW; Telenius A; Lai D; Teater M; Kridel R; Savage KJ; Sehn LH; Morin RD; Marra MA; Shah SP; Connors JM; Gascoyne RD; Scott DW; Melnick AM; Steidl C
Cancer Discov; 2019 Apr; 9(4):546-563. PubMed ID: 30705065
[TBL] [Abstract][Full Text] [Related]
43. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status.
Pike BL; Greiner TC; Wang X; Weisenburger DD; Hsu YH; Renaud G; Wolfsberg TG; Kim M; Weisenberger DJ; Siegmund KD; Ye W; Groshen S; Mehrian-Shai R; Delabie J; Chan WC; Laird PW; Hacia JG
Leukemia; 2008 May; 22(5):1035-43. PubMed ID: 18288132
[TBL] [Abstract][Full Text] [Related]
44. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
Xie S; Wei F; Sun YM; Gao YL; Pan LL; Tan MJ; Wang SD; Ding J; Chen Y
Haematologica; 2020 Apr; 105(4):1021-1031. PubMed ID: 31289198
[TBL] [Abstract][Full Text] [Related]
45. Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.
Zhang YW; Zhang J; Li J; Zhu JF; Yang YL; Zhou LL; Hu ZL; Zhang F
Leuk Lymphoma; 2015; 56(8):2429-38. PubMed ID: 25487076
[TBL] [Abstract][Full Text] [Related]
46. Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.
Larrea E; Fernandez-Mercado M; Guerra-Assunção JA; Wang J; Goicoechea I; Gaafar A; Ceberio I; Lobo C; Okosun J; Enright AJ; Fitzgibbon J; Lawrie CH
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233721
[TBL] [Abstract][Full Text] [Related]
47. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
Alcaide M; Yu S; Bushell K; Fornika D; Nielsen JS; Nelson BH; Mann KK; Assouline S; Johnson NA; Morin RD
Clin Chem; 2016 Sep; 62(9):1238-47. PubMed ID: 27440511
[TBL] [Abstract][Full Text] [Related]
48. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
49. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
Zheng S; Houseman EA; Morrison Z; Wrensch MR; Patoka JS; Ramos C; Haas-Kogan DA; McBride S; Marsit CJ; Christensen BC; Nelson HH; Stokoe D; Wiemels JL; Chang SM; Prados MD; Tihan T; Vandenberg SR; Kelsey KT; Berger MS; Wiencke JK
Neuro Oncol; 2011 Mar; 13(3):280-9. PubMed ID: 21339190
[TBL] [Abstract][Full Text] [Related]
50. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.
Velichutina I; Shaknovich R; Geng H; Johnson NA; Gascoyne RD; Melnick AM; Elemento O
Blood; 2010 Dec; 116(24):5247-55. PubMed ID: 20736451
[TBL] [Abstract][Full Text] [Related]
51. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
[TBL] [Abstract][Full Text] [Related]
52. Deregulation of H3K27 methylation in cancer.
Martinez-Garcia E; Licht JD
Nat Genet; 2010 Feb; 42(2):100-1. PubMed ID: 20104248
[TBL] [Abstract][Full Text] [Related]
53. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
55. Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors.
Sharma V; Malgulwar PB; Purkait S; Patil V; Pathak P; Agrawal R; Kulshreshtha R; Mallick S; Julka PK; Suri A; Sharma BS; Suri V; Sharma MC; Sarkar C
Carcinogenesis; 2017 Feb; 38(2):152-161. PubMed ID: 27993893
[TBL] [Abstract][Full Text] [Related]
56. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
[TBL] [Abstract][Full Text] [Related]
57. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
[TBL] [Abstract][Full Text] [Related]
58. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
59. Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.
Hao B; Sun M; Zhang M; Zhao X; Zhao L; Li B; Zhai L; Liu P; Hu H; Xu JY; Tan M
J Proteomics; 2020 Feb; 213():103614. PubMed ID: 31846764
[TBL] [Abstract][Full Text] [Related]
60. Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
Mohamed G; Talima S; Li L; Wei W; Rudzki Z; Allam RM; Simmons W; Tao Q; Murray PG
Pathol Oncol Res; 2019 Jul; 25(3):1223-1231. PubMed ID: 30739251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
